Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, announced today that its investigational therapy, ...

The FDA has introduced a new fast-track review system for three psychedelic drug programs targeting PTSD and depression, potentially cutting approval review times to one or two months once ...

The FDA announced on April 24, 2026, that it has granted a new class of accelerated review vouchers to three psychedelic drug ...

Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental ...

The FDA said it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, ...

The agency issued priority vouchers for 3 experimental new drugs using psilocybin and methylone, amid Trump's ...

FDA fast‑tracks three psychedelic drugs after Trump order speeding research on depression and PTSD treatments.

In November 2025, New York City voters approved four land use-related City Charter amendments, one of which is the Affordable ...

Sponsored - The following content is created on behalf of OneSpartanburg, Inc and does not reflect the opinions of Gray Media or its editorial staff. To learn more about OneSpartanburg, Inc, visit www ...

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ...

The FDA has granted fast track and rolling review status to Celltrion’s CT-P71, a Nectin-4 targeting ADC for treating advanced urothelial carcinoma. CT-P71 functions by targeting Nectin-4, a protein ...

Climb Bio has won the Food and Drug Administration's fast-track designation for its proposed budoprutug treatment for the rare kidney disease primary membranous nephropathy, or pMN. The FDA's ...